Some brighter views
21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."
Pages
55
Language
English
Published on
21/06/22
You may also be interested by these reports :
05/12/25
In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation ...
05/12/25
On the back of promising operating results, which also prompted management to upgrade its guidance, our estimates reset higher. This is commendable, ...
05/12/25
We have incorporated the actual figures for the FY24/25 ending in June 2025. While the recurring EBIT was in line with our forecast (€44.2m vs ...
03/12/25
Despite challenges that have reduced our target price, Demant still presents a significant upside. The company is poised to benefit from: 1) new ...